Starboard Value has taken a significant stake in Pfizer, said people familiar with the matter. The drug giant's stock has dropped significantly since its 2021 COVID-19 vaccine rollout. Starboard has recently taken positions in Starbucks and Match. Insider Today NSIDER TODAY Sign up to get the inside scoop on today's biggest stories in markets, tech, and business — delivered daily. Read preview Bull Thanks for signing up! Go to newsletter preferences Thanks for signing up! Access your favorite topics in a pe ...

Activist investor Starboard Value has a roughly $1 billion stake in pharmaceutical giant Pfizer and is seeking to mount a turnaround at the struggling company, according to people familiar with the matter.The activist's exact plans could not be learned, but Starboard has approached former Pfizer CEO Ian Read and ex-finance chief Frank D'Amelio, both of whom have expressed interest in supporting Starboard's turnaround, said the people.Starboard believes that Pfizer's current leadership, under CEO Albert Bour ...

My previous bullish thesis about Pfizer's stock (NYSE: PFE ) (NEOE: PFE:CA ) aged well as the stock delivered a 5% total return since early July. The stock outperformed the broader U.S. market over the same period. I am a highly experienced Chief Financial Officer (CFO) with a strong background in the oilfield and real estate industries. With over a decade of experience in finance, I have led numerous complex due diligence efforts and M&A transactions, both domestically and internationally.In recent years, ...

Pfizer has prepared for today's challenges... and has set big goals. Pfizer (PFE -0.21%) has been around for 175 years, selling a wide range of drugs in various treatment areas over time. But this pharma giant truly became a household name a few years ago. Pfizer made headlines with its coronavirus vaccine, which turned out to become the world's best-selling pharmaceutical product. And this helped Pfizer reach a record of more than $100 billion in annual revenue in 2022. But over the past year and a half, a ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Hello and happy Tuesday! Today, we're unpacking a shocking move from Pfizer. The pharmaceutical giant last week announced it would voluntarily withdraw its sickle cell disease therapy, Oxbryta, from worldwide markets — to the surprise of doctors, patients and investors.Here's why the drug is important: Oxbryta is one of at l ...

Retirement is complicated and you only get once chance to do it right. Don't miss out because you didn't know what was out there.The Retirement Forum provides actionable ideals, a high-yield safe retirement portfolio, and macroeconomic outlooks, all to help you maximize your capital and your income. We search the entire market to help you maximize returns.Pfizer Inc. (NYSE: PFE ) hasn't been becoming famous off of obesity drugs like many other pharmaceutical companies. In fact, the company has seen weakness ...

Everybody loves dividends, as they provide a passive income stream, limit drawdowns in other positions, and provide more than one way to profit from an investment.And when considering dividend-paying stocks, those with a history of boosting their payout are prime considerations, reflecting their commitment to increasingly rewarding shareholders.Of course, consistent dividend hikes also reflect a successful nature, opting to share a portion of profits.For those seeking companies that have consistently booste ...

Pfizer (NYSE: PFE ) has been strategically increasing their business exposure in the oncology franchise by developing more cancer drugs to drive their future growth. I think the acquisition of Seagen could strengthen their Antibody-Drug Conjugate (ADC) technology. I am initiating with a 'Buy' rating withMore than 15 years of professional investment experience in global equities across all sectors. My investment style is fundamental, bottom-up, long-term, and quality growth-oriented. I am seeking companies s ...

Shares of Pfizer (NYSE: PFE ) have gone nowhere this year, in large part because investors feared a revenue cliff with regard to the company’s COVID-19 products. Although shares have widely disappointed in 2024, I believe Pfizer remains an attractive capitalAnalyst’s Disclosure: I/we have a beneficial long position in the shares of PFE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other th ...

The latest trading session saw Pfizer (PFE) ending at $28.97, denoting a +0.14% adjustment from its last day's close. This move lagged the S&P 500's daily gain of 0.4%. At the same time, the Dow added 0.62%, and the tech-heavy Nasdaq gained 0.6%.Shares of the drugmaker witnessed a gain of 0.63% over the previous month, beating the performance of the Medical sector with its loss of 2.27% and underperforming the S&P 500's gain of 1.71%.The investment community will be closely monitoring the performance of Pfi ...